| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/HR.2012.157 |
| P698 | PubMed publication ID | 23051659 |
| P2093 | author name string | Anastasios N Lasaridis | |
| Maria I Pikilidou | |||
| Anastasia G Ptinopoulou | |||
| P2860 | cites work | Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy | Q72553570 |
| Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release | Q74088802 | ||
| Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo | Q74266636 | ||
| Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity | Q80066228 | ||
| Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening | Q80087723 | ||
| Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes | Q80797117 | ||
| Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker | Q81894160 | ||
| Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? | Q83854650 | ||
| Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? | Q83854659 | ||
| Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure | Q24521489 | ||
| Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| Acute myocardial infarction and renal dysfunction: a high-risk combination | Q28193845 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 | ||
| Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). | Q31437386 | ||
| Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis | Q33226226 | ||
| ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses | Q33576830 | ||
| Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor | Q33688695 | ||
| Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
| HFSA 2010 Comprehensive Heart Failure Practice Guideline | Q34124756 | ||
| Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial | Q34502430 | ||
| Role for $beta;-blockers in the management of diabetic kidney disease | Q35544593 | ||
| Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials | Q35620731 | ||
| Differential effects of calcium antagonist subclasses on markers of nephropathy progression | Q35776372 | ||
| Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. | Q35995026 | ||
| Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. | Q36153078 | ||
| The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems | Q36312545 | ||
| Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation | Q36315475 | ||
| Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study | Q36432084 | ||
| How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis | Q36629674 | ||
| Aldosterone blockade: an emerging strategy for abrogating progressive renal disease | Q36637346 | ||
| Acute renal failure in the elderly: particular characteristics. | Q36679512 | ||
| Ca2+ channel subtypes and pharmacology in the kidney | Q36739124 | ||
| Should beta-blockers be used to control hypertension in people with chronic kidney disease? | Q36942115 | ||
| Aliskiren: the first direct renin inhibitor for hypertension | Q37000071 | ||
| Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
| Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence | Q37428041 | ||
| Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? | Q37444731 | ||
| Should diuretics always be included as initial antihypertensive management in early-stage CKD? | Q37534067 | ||
| Endothelin antagonists and resistant hypertension in chronic kidney disease | Q37760763 | ||
| Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers | Q37763195 | ||
| Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. | Q37852930 | ||
| National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q39513412 | ||
| An Overview of the Pharmacodynamic Properties and Therapeutic Potential of Combined α- and β-Adrenoceptor Antagonists | Q40487133 | ||
| Endothelin receptors in normal and diseased kidneys | Q41039212 | ||
| Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection | Q41057180 | ||
| Glucose and cholesterol elevations during thiazide therapy: Intention-to-treat versus actual on-therapy experience | Q41681669 | ||
| Nephrologists neglect administration of betablockers to dialysed diabetic patients. | Q41682956 | ||
| Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine | Q41704270 | ||
| Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy | Q42164528 | ||
| A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease | Q42661083 | ||
| Changes in renal risk factors versus renal function outcome during follow-up in a population-based cohort study | Q43201087 | ||
| Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine | Q43265134 | ||
| Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy | Q43277300 | ||
| A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial | Q43277549 | ||
| Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators | Q43565969 | ||
| Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). | Q43601348 | ||
| Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients | Q43732835 | ||
| Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study | Q43996549 | ||
| Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect | Q44090671 | ||
| Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 | ||
| Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action | Q44438468 | ||
| Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. | Q44460506 | ||
| The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study | Q44493977 | ||
| Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). | Q44519453 | ||
| Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism | Q44530748 | ||
| Microalbuminuria and oxidative stress in essential hypertension | Q44839973 | ||
| Effect of aldosterone on renal transforming growth factor-beta | Q44886467 | ||
| Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. | Q45145783 | ||
| Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. | Q45155019 | ||
| beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality | Q45238137 | ||
| Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease | Q46099812 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study | Q46238883 | ||
| Renal afferent denervation prevents hypertension in rats with chronic renal failure | Q46354302 | ||
| Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial | Q46378094 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH | Q46455413 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 | ||
| Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes | Q46802773 | ||
| Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? | Q46970575 | ||
| Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin | Q48007234 | ||
| Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. | Q50735530 | ||
| Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. | Q50762321 | ||
| Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. | Q51574871 | ||
| Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. | Q51915845 | ||
| Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. | Q54301381 | ||
| THE PHARMACOLOGY OF CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS | Q56519158 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes | Q57605349 | ||
| Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial | Q57702605 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| Prevention of microalbuminuria in patients with type 2 diabetes and hypertension | Q57789874 | ||
| Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure | Q67419807 | ||
| Plasma aldosterone concentrations in chronic renal disease | Q70233120 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Blood pressure and end-stage renal disease in men | Q71574790 | ||
| Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study | Q71777734 | ||
| ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells | Q72200631 | ||
| P433 | issue | 2 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 91-101 | |
| P577 | publication date | 2012-10-11 | |
| P1433 | published in | Hypertension Research | Q15762136 |
| P1476 | title | The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review | |
| P478 | volume | 36 |
| Q93066911 | Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease |
| Q26825409 | Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease |
| Q36925395 | Blood pressure and antihypertensive medication profile in a multiethnic Asian population of stable chronic kidney disease patients. |
| Q51741240 | Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. |
| Q40873034 | Conservative management of staghorn calculi: a single-centre experience |
| Q38800239 | Global cardiovascular protection in chronic kidney disease |
| Q28659091 | Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats |
| Q37271294 | Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney |
| Q35694558 | Nighttime Systolic Blood-Pressure Load Is Correlated with Target-Organ Damage Independent of Ambulatory Blood-Pressure Level in Patients with Non-Diabetic Chronic Kidney Disease |
| Q59804823 | Renal Dysfunction among Ghanaians Living with Clinically Diagnosed Hypertension in the Asutifi-South District: A Cross-Sectional Descriptive Study at the St. Elizabeth Hospital, Hwidiem |
| Q34580946 | Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease |
| Q39780663 | Role of mesenchymal stem cells versus angiotensin converting enzyme inhibitor in kidney repair |
| Q41054597 | The Effect of Chinese rhubarb, Rheum officinale, with and without benazepril on the progression of naturally occurring chronic kidney disease in cats |
Search more.